The thalidomide tragedy is now, and always will be, part of Grünenthal's company history. Grünenthal and its family shareholders greatly regret the consequences of the thalidomide tragedy. It is a matter of moral importance to Grünenthal to be actively involved in charitable efforts to improve the situation of thalidomide-affected people on a sustainable basis. We seek to work together with those affected by thalidomide to devise projects for the provision of specific needs-based support.
On 28 February 2017, the Fourth Amendment of the Contergan Foundation Act was published in the German Federal Law Gazette. It has now entered into force retroactively with effect from 1 January 2017. The document as PDF including all changes can be found under this link:More information
Our position is clear: There is an established financial support system for people affected by Thalidomide throughout Europe. The Contergan foundation*, in which Grünenthal has paid more than 100 million Euros, supports affected individuals in 38 countries with monthly individual payments between 662 € and 7.620 € including those affected in Spain, provided that their mothers took a Thalidomide containing product from Grünenthal.
Grünenthal Pharma has set up a program to support the costs of the translations into German language of the relevant medical documents and applications of Spanish individuals willing to apply to the Contergan Foundation in Germany.